keyword
MENU ▼
Read by QxMD icon Read
search

Colorectal cancer blood tests

keyword
https://www.readbyqxmd.com/read/28218734/-lesions-detected-in-six-spanish-colorectal-cancer-screening-population-based-programmes-cribea-project-spain
#1
Isabel Portillo Villares, Eunate Arana-Arri, Isabel Idigoras Rubio, Josep Alfons Espinás Piñol, Francisco Pérez Riquelme, Mariola de la Vega Prieto, Alvaro González Aledo, Elena Oceja Setien, Mercedes Vanaclocha Espi, Josefa Ibáñez Cabanell, Dolores Salas Trejo
OBJECTIVE: In this study, the results of six Colorectal Cancer Screening Population Programmes are shown (Catalonia, Valence, Murcia, Cantabria, the Basque Country and the Canary Islands collected between 2005 and 2012. These programmes use the faeces occult blood test (FOBt) biennial. Objective: To determine and compare the results of lesions detected by the programmes, participation, sex, age and test used. METHODS: Retrospective cohort study based on people invited, aged between 50-74 years, in at least a complete round...
February 20, 2017: Revista Española de Salud Pública
https://www.readbyqxmd.com/read/28214250/colorectal-cancer-screening-adherence-in-selected-disabilities-over-10-years
#2
Chelsea B Deroche, Suzanne W McDermott, Joshua R Mann, James W Hardin
INTRODUCTION: Colorectal cancer (CRC) is the second leading cause of cancer mortality in the U.S.; however, if the population aged 50 years or older received routine screening, approximately 60% of these deaths could be eliminated. This study investigates whether adults, aged 50-75 years, with one of three disabilities (blind/low vision [BLV], intellectual disability [ID], spinal cord injury [SCI]) receive CRC screening at rates equivalent to adults without the three disabilities, by accounting for combinations of recommended CRC screenings during a 10-year period (colonoscopy, sigmoidoscopy, fecal occult blood test)...
February 14, 2017: American Journal of Preventive Medicine
https://www.readbyqxmd.com/read/28210537/multilevel-predictors-of-colorectal-cancer-testing-modality-among-publicly-and-privately-insured-people-turning-50
#3
Stephanie B Wheeler, Tzy-Mey Kuo, Anne Marie Meyer, Christa E Martens, Kristen M Hassmiller Lich, Florence K L Tangka, Lisa C Richardson, Ingrid J Hall, Judith Lee Smith, Maria E Mayorga, Paul Brown, Trisha M Crutchfield, Michael P Pignone
Understanding multilevel predictors of colorectal cancer (CRC) screening test modality can help inform screening program design and implementation. We used North Carolina Medicare, Medicaid, and private, commercially available, health plan insurance claims data from 2003 to 2008 to ascertain CRC test modality among people who received CRC screening around their 50th birthday, when guidelines recommend that screening should commence for normal risk individuals. We ascertained receipt of colonoscopy, fecal occult blood test (FOBT) and fecal immunochemical test (FIT) from billing codes...
June 2017: Preventive Medicine Reports
https://www.readbyqxmd.com/read/28210082/multitarget-stool-dna-tests-increases-colorectal-cancer-screening-among-previously-noncompliant-medicare-patients
#4
Mark Prince, Lynn Lester, Rupal Chiniwala, Barry Berger
AIM: To determine the uptake of noninvasive multitarget stool DNA (mt-sDNA) in a cohort of colorectal cancer (CRC) screening non-compliant average-risk Medicare patients. METHODS: This cross sectional primary care office-based study examined mt-sDNA uptake in routine clinical practice among 393 colorectal cancer screening non-compliant Medicare patients ages 50-85 ordered by 77 physicians in a multispecialty group practice (USMD Physician Services, Dallas, TX) from October, 2014-September, 2015...
January 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28188568/a-comprehensive-electronic-health-record-based-patient-navigation-module-including-technology-driven-colorectal-cancer-outreach-and-education
#5
Sunny Ajeesh, Rustveld Luis
The purpose of this concept paper is to propose an innovative multifaceted patient navigation module embedded in the Electronic Health Record (EHR) to address barriers to efficient and effective colorectal cancer (CRC) care. The EHR-based CRC patient navigation module will include several patient navigation features: (1) CRC screening registry; (2) patient navigation data, including CRC screening data, outcomes of patient navigation including navigation status (CRC screening referrals, fecal occult blood test (FOBT) completed, colonoscopy scheduled and completed, cancelations, reschedules, and no-shows); (3) CRC counseling aid; and 4) Web-based CRC education application including interactive features such as a standardized colonoscopy preparation guide, modifiable CRC risk factors, and links to existing resources...
February 10, 2017: Journal of Cancer Education: the Official Journal of the American Association for Cancer Education
https://www.readbyqxmd.com/read/28182647/performance-analysis-of-a-machine-learning-flagging-system-used-to-identify-a-group-of-individuals-at-a-high-risk-for-colorectal-cancer
#6
Yaron Kinar, Pinchas Akiva, Eran Choman, Revital Kariv, Varda Shalev, Bernard Levin, Steven A Narod, Ran Goshen
Individuals with colorectal cancer (CRC) have a tendency to intestinal bleeding which may result in mild to severe iron deficiency anemia, but for many colon cancer patients hematological abnormalities are subtle. The fecal occult blood test (FOBT) is used as a pre-screening test whereby those with a positive FOBT are referred to colonscopy. We sought to determine if information contained in the complete blood count (CBC) report coud be processed automatically and used to predict the presence of occult colorectal cancer (CRC) in the setting of a large health services plan...
2017: PloS One
https://www.readbyqxmd.com/read/28179316/correlation-of-blood-t-cells-to-intratumoural-density-and-location-of-cd3-and-cd8-t-cells-in-colorectal-cancer
#7
Hanne R Hagland, Dordi Lea, Martin M Watson, Kjetil Søreide
AIM: To test the feasibility of conducting parallel analyses of circulating T-cells in blood and intratumoural T-cells in colorectal cancer. A pre-operative 'liquid biopsy' to determine immune status would facilitate clinical decision-making. MATERIALS AND METHODS: A total of 18 patients with stage I-III colorectal cancer (CRC) were included. Blood was analyzed for T-cell type (CD3(+), CD4(+) and CD8(+)) and count using flow cytometry. Intratumoural T-cells were stained using immunohistochemistry and quantified by digital pathology...
2017: Anticancer Research
https://www.readbyqxmd.com/read/28170370/development-of-a-gene-panel-for-next-generation-sequencing-of-clinically-relevant-mutations-in-cell-free-dna-from-cancer-patients
#8
Umberto Malapelle, Clara Mayo de-Las-Casas, Danilo Rocco, Monica Garzon, Pasquale Pisapia, Nuria Jordana-Ariza, Maria Russo, Roberta Sgariglia, Caterina De Luca, Francesco Pepe, Alejandro Martinez-Bueno, Daniela Morales-Espinosa, María González-Cao, Niki Karachaliou, Santiago Viteri Ramirez, Claudio Bellevicine, Miguel Angel Molina-Vila, Rafael Rosell, Giancarlo Troncone
BACKGROUND: When tumour tissue is unavailable, cell-free DNA (cfDNA)can serve as a surrogate for genetic analyses. Because mutated alleles in cfDNA are usually below 1%, next-generation sequencing (NGS)must be narrowed to target only clinically relevant genes. In this proof-of-concept study, we developed a panel to use in ultra-deep sequencing to identify such mutations in cfDNA. METHODS: Our panel ('SiRe') covers 568 mutations in six genes (EGFR, KRAS, NRAS, BRAF, cKIT and PDGFRα)involved in non-small-cell lung cancer (NSCLC), gastrointestinal stromal tumour, colorectal carcinoma and melanoma...
February 7, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28167157/replacing-the-guaiac-fecal-occult-blood-test-with-the-fecal-immunochemical-test-increases-proportion-of-individuals-screened-in-a-large-healthcare-setting
#9
Ali Akram, Derek Juang, Ranier Bustamante, Lin Liu, Ashley Earles, Samuel B Ho, Jessica Wang-Rodriguez, James Allison, Samir Gupta
BACKGROUND & AIMS: The most commonly used non-invasive test for colorectal cancer (CRC) screening has been the guaiac fecal occult blood test (gFOBT). The fecal immunochemical test (FIT) detects CRC and colorectal polyps with higher levels of sensitivity than the gFOBT, and may be more acceptable to patients. However, the FIT has not replaced the gFOBT in many clinical settings. We analyzed data from a large healthcare system that replaced the gFOBT with the FIT to determine the effects on CRC screening...
February 3, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28155091/epi-procolon-%C3%A2-2-0-ce-a-blood-based-screening-test-for-colorectal-cancer
#10
Yvette N Lamb, Sohita Dhillon
Epi proColon(®) 2.0 CE is a blood-based test designed to aid in the early detection of colorectal cancer. The test comprises a qualitative assay for the polymerase chain reaction (PCR) detection of methylated Septin9 DNA, the presence of which is associated with colorectal cancer: however, positive results should be verified by colonoscopy or sigmoidoscopy. Epi proColon(®) 2.0 CE discriminated between patients with colorectal cancer and healthy controls with high clinical sensitivity and specificity in pivotal case-control studies...
February 2, 2017: Molecular Diagnosis & Therapy
https://www.readbyqxmd.com/read/28155016/power-of-screening-tests-for-colorectal-cancer-enhanced-by-high-levels-of-m2-pk-in-addition-to-fobt
#11
Cristina Zaccaro, Ilaria Maria Saracino, Giulia Fiorini, Natale Figura, John Holton, Valentina Castelli, Valeria Pesci, Luigi Gatta, Dino Vaira
Colorectal cancer (CRC) is a multistep process that involves adenoma-carcinoma sequence. CRC can be prevented by routine screening, which can detect precancerous lesions. The aim of this study is to clarify whether faecal occult blood test (i-FOBT), tumor M2 pyruvate kinase (t-M2-PK), and endocannabinoid system molecules (cannabinoid receptors type 1-CB1, type 2-CB2, and fatty acid amide hydrolase-FAAH) might represent better diagnostic tools, alone or in combination, for an early diagnosis of CRC. An immunochemical FOB test (i-FOBT) and quantitative ELISA stool test for t-M2-PK were performed in 127 consecutive patients during a 12 month period...
February 2, 2017: Internal and Emergency Medicine
https://www.readbyqxmd.com/read/28154606/lavandula-angustifolia-mill-oil-and-its-active-constituent-linalyl-acetate-alleviate-pain-and-urinary-residual-sense-after-colorectal-cancer-surgery-a-randomised-controlled-trial
#12
So Hyun Yu, Geun Hee Seol
Pain and urinary symptoms following colorectal cancer (CRC) surgery are frequent and carry a poor recovery. This study tested the effects of inhalation of Lavandula angustifolia Mill. (lavender) oil or linalyl acetate on pain relief and lower urinary tract symptoms (LUTS) following the removal of indwelling urinary catheters from patients after CRC surgery. This randomised control study recruited 66 subjects with indwelling urinary catheters after undergoing CRC surgery who later underwent catheter removal...
2017: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/28142309/interval-cancers-in-a-guaiac-based-colorectal-cancer-screening-programme-consequences-on-sensitivity
#13
Johannes Blom, Sven Törnberg
Objective To evaluate interval cancers in the population-based colorectal cancer screening programme of Stockholm/Gotland, Sweden. Methods From 2008, individuals aged 60-69 were invited to colorectal cancer screening using biennial guaiac-based faecal occult blood test (Hemoccult®). Interval cancers, defined as colorectal cancer among participants not diagnosed by the screening programme but registered in the Swedish cancer register, were evaluated by cross-checking the screening histories for all cancers in the region 2008-2012...
January 1, 2017: Journal of Medical Screening
https://www.readbyqxmd.com/read/28139497/the-expression-and-significance-of-feces-cyclooxygensae-2-mrna-in-colorectal-cancer-and-colorectal-adenomas
#14
Xiaofeng Li, Lixia Kong, Suhuan Liao, Jing Lu, Lin Ma, Xiaohua Long
BACKGROUND/AIM: This study aims to explore the expression and significance of feces cyclooxygensae-2 (COX-2) mRNA in colorectal cancer and colorectal adenomas. MATERIALS AND METHODS: The expression of feces COX-2 mRNA in colorectal cancer (n = 28), colorectal adenomas (n = 54), and normal control group (n = 11) were examined by reverse transcriptase polymerase chain reaction (RT-PCR). The positive rate of fecal occult blood test (FOBT) were detected in colorectal cancer (n = 30), colorectal adenomas (n = 56), and normal control group (n = 11); the sensitivity of the two methods was also compared...
January 2017: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://www.readbyqxmd.com/read/28125854/written-instructions-to-patients-to-confirm-pathology-results-is-this-effective-in-the-transmission-of-results
#15
Ashwin Patwardhan, Simon Wilkins, Margaret Staples, Paul J McMurrick
BACKGROUND: Bowel cancer is the second most common internal malignancy in Australia. Bowel cancer is suited to community screening methods such as faecal occult blood testing and colonoscopy. Typical reporting of histopathology results after colonoscopy takes 3-5 days. Patients were given written instructions to call the clinician within 3-5 days to discuss the histopathology results. The objective of the study was to perform an audit whether patients call the clinician to discuss their histopathology results after undergoing a colonoscopy, gastroscopy or both...
January 26, 2017: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/28124492/helicobacter-pylori-infection-is-an-independent-risk-factor-of-early-and-advanced-colorectal-neoplasm
#16
Tae Jun Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim, Sun-Young Baek, Kyunga Kim, Sung Noh Hong
BACKGROUND: The role of Helicobacter pylori (H. pylori) in the development of colorectal neoplasm remains controversial. We examined the association between H. pylori infection and colorectal neoplasm in a large sample of healthy participants who underwent screening colonoscopy. METHODS: A cross-sectional study of 8916 men, who participated in a regular health-screening examination that included an H. pylori-specific immunoglobulin G antibody test and colonoscopy, was conducted to evaluate the association between H...
January 26, 2017: Helicobacter
https://www.readbyqxmd.com/read/28124380/methylated-free-circulating-hpp1-dna-is-an-early-response-marker-in-patients-with-metastatic-colorectal-cancer
#17
Andreas Herbst, Nikolay Vdovin, Sanja Gacesa, Alexander Philipp, Dorothea Nagel, Lesca M Holdt, Mark Op den Winkel, Volker Heinemann, Petra Stieber, Ullrich Graeven, Anke Reinacher-Schick, Dirk Arnold, Ingrid Ricard, Ulrich Mansmann, Susanna Hegewisch-Becker, Frank T Kolligs
Detection of methylated free-circulating DNA (mfcDNA) for hyperplastic polyposis 1 (HPP1) in blood is correlated with a poor prognosis for patients with metastatic colorectal cancers (mCRC). Here, we analyzed the plasma levels of HPP1 mfcDNA in mCRC patients treated with a combination therapy containing a fluoropyrimidine, oxaliplatin and bevacizumab to test whether HPP1 mfcDNA is a suitable prognostic and response biomarker. From 467 patients of the prospective clinical study AIO-KRK-0207, mfcDNA was isolated from plasma samples at different time points and bisulfite-treated mfcDNA was quantified using methylation specific PCR...
January 25, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28117881/comparative-effectiveness-of-screening-strategies-for-colorectal-cancer
#18
Afsaneh Barzi, Heinz-Josef Lenz, David I Quinn, Sarmad Sadeghi
BACKGROUND: Screening for colorectal cancer (CRC) has been successful in decreasing the incidence and mortality from CRC. Although new screening tests have become available, their relative impact on CRC outcomes remains unexplored. This study compares the outcomes of various screening strategies on CRC outcomes. METHODS: A Markov model representing the natural history of CRC was built and validated against empiric data from screening trials as well as the Microstimulation Screening Analysis (MISCAN) model...
January 24, 2017: Cancer
https://www.readbyqxmd.com/read/28106345/blood-based-detection-of-ras-mutations-to-guide-anti-egfr-therapy-in-colorectal-cancer-patients-concordance-of-results-from-circulating-tumor-dna-and-tissue-based-ras-testing
#19
Wolff Schmiegel, Rodney J Scott, Susan Dooley, Wendy Lewis, Cliff J Meldrum, Peter Pockney, Brian Draganic, Steve Smith, Chelsee Hewitt, Hazel Philimore, Amanda Lucas, Elva Shi, Kateh Namdarian, Timmy Chan, Danilo Acosta, Su Ping-Chang, Andrea Tannapfel, Anke Reinacher-Schick, Waldemar Uhl, Christian Teschendorf, Heiner Wolters, Josef Stern, Richard Viebahn, Helmut Friess, Klaus-Peter Janssen, Ulrich Nitsche, Julia Slotta-Huspenina, Michael Pohl, Deepak Vangala, Alexander Baraniskin, Barbara Dockhorn-Dworniczak, Susanne Hegewisch-Becker, Philippe Ronga, Daniel L Edelstein, Frederick S Jones, Stephan Hahn, Stephen B Fox
An accurate blood-based RAS mutation assay to determine eligibility of metastatic colorectal cancer (mCRC) patients for anti-EGFR therapy would benefit clinical practice by better informing decisions to administer treatment independent of tissue availability. The objective of this study was to determine the level of concordance between plasma and tissue RAS mutation status in patients with mCRC to gauge whether blood-based RAS mutation testing is a viable alternative to standard-of-care RAS tumor testing. RAS testing was performed on plasma samples from newly diagnosed metastatic patients, or from recurrent mCRC patients using the highly sensitive digital PCR technology, BEAMing (beads, emulsions, amplification, and magnetics), and compared with DNA sequencing data of respective FFPE (formalin-fixed paraffin-embedded) tumor samples...
February 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28101227/downregulation-of-mir-23b-in-plasma-is-associated-with-poor-prognosis-in-patients-with-colorectal-cancer
#20
Chang-Hua Kou, Tian Zhou, Xi-Lin Han, Hui-Jie Zhuang, Hai-Xin Qian
MicroRNAs (miRNAs) are short, non-coding RNA molecules that act as regulators of gene expression. Circulating blood miRNAs have potential as cancer biomarkers. The main objective of the present study was to assess the effect of miRNA-23b (miR-23b) expression in plasma on the diagnosis and prognosis of colorectal cancer (CRC). Reverse transcription-quantitative polymerase chain reaction (PCR) was used to measure miR-23b expression levels, and methylation-specific PCR was used to test the promoter methylation status...
December 2016: Oncology Letters
keyword
keyword
24481
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"